Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
SRAX to Present at the 8th Annual LD Micro Invitational

2018-05-29 accesswire
LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Social Reality, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management and distribution technology platform company, will participate in the 8th Annual LD Micro Invitational.
SCRID SRAX SCRI

6
Social Reality's (SRAX) CEO Christopher Miglino on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Social Reality Inc. (NASDAQ:SRAX) Q1 2018 Results Earnings Conference Call May 15, 2018 4:30 PM ET
SCRID SRAX SCRI

6
SRAX to Present at the Planet MicroCap Showcase 2018 on April 25 in Las Vegas

2018-04-18 accesswire
LOS ANGELES, CA / ACCESSWIRE / April 18, 2018 / Social Reality, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management and distribution technology platform company, will present at the Planet MicroCap Showcase at 9:30 am PDT on April 25, 2018, and will conduct 1-on-1 meetings on April 26, 2018.
SCRID SRAX SCRI

8
Social Reality's (SRAX) CEO Christopher Miglino on Q4 2017 Results - Earnings Call Transcript

2018-04-02 seekingalpha - 2
Good day. And welcome to the SRAX Fourth Quarter and Full Year 2017 Results Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Kirsten Chapman of LHA Investor Relations. Please go ahead, Ma’am.
SCRID SRAX SCRI

77
Short Sellers Look Quite Aggressive Against Bitcoin, Cryptocurrency and Blockchain Stocks

2018-03-12 247wallst - 5
In the world of bitcoin, blockchain and cryptocurrency trading, there has been a story that went from rags to riches and back to rags in a pretty short time. The underlying technology is of course set to remain in place. Still, many investors and speculators think that bitcoin itself and the subsequent cryptocurrencies are just the next bubble.
OSTK RIOT SCRID LBCC SQ SQNXF SRAX SCRI MARA LTEA GROW DPW

6
BRIEF-Social Reality Says ‍Alpha Release Of Blockchain Technology Big Platform To A Limited, By Invitation Only Group Of Users​

2018-03-12 reuters
* SOCIAL REALITY INC - ALPHA RELEASE OF BLOCKCHAIN TECHNOLOGY BIG PLATFORM TO A LIMITED, BY INVITATION ONLY GROUP OF USERS Source text for Eikon: Further company coverage:
SCRID SRAX SCRI

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...